{"id":"gb491-fulvestrant","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Vaginal bleeding/discharge"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GB491 is a novel SERD that enhances the activity of fulvestrant, a known estrogen receptor antagonist and degrader. The combination targets estrogen receptor-positive breast cancer by promoting receptor degradation and preventing estrogen-driven proliferation. This dual mechanism aims to overcome resistance to standard endocrine therapies.","oneSentence":"GB491 is a selective estrogen receptor degrader (SERD) that works synergistically with fulvestrant to degrade estrogen receptors and block estrogen signaling in hormone receptor-positive breast cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:42.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative metastatic breast cancer (in combination with fulvestrant)"}]},"trialDetails":[{"nctId":"NCT05054751","phase":"PHASE3","title":"GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2021-09-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["test drug + Fulvestrant"],"phase":"phase_3","status":"active","brandName":"GB491+ Fulvestrant","genericName":"GB491+ Fulvestrant","companyName":"Genor Biopharma Co., Ltd.","companyId":"genor-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GB491 is a selective estrogen receptor degrader (SERD) that works synergistically with fulvestrant to degrade estrogen receptors and block estrogen signaling in hormone receptor-positive breast cancer cells. Used for Hormone receptor-positive, HER2-negative metastatic breast cancer (in combination with fulvestrant).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}